Arcline Investment Management is setting the stage for a $1.06 billion U.S. IPO that could value aerospace component maker Arxis at $11.2 billion. The deal will issue 37.7 million shares priced between $25 and $28, positioning the company among the largest defence‑linked listings in the pipeline that appeal to investors seeking exposure to resilient defense supply chains today.

Geopolitical tensions have sharpened appetite for aerospace and defense assets, a trend mirrored by recent filings from AEVEX and Elmet. Arxis serves aerospace, defense, medical technology, and specialized industrial markets, giving it diversified exposure within mission‑critical supply chains and reinforcing its attractiveness to institutional buyers for investors looking to hedge against market volatility in 2024.

Capital International Investors, Capital Research Global Investors, Janus Henderson Investors, and T. Rowe Price have signaled interest in buying up to $400 million of shares, underscoring confidence in the offering. Proceeds will primarily be used to reduce debt and support ongoing operations, providing Arcline with a clear exit pathway while preserving cash flow for capital expenditures.

Arxis will list on Nasdaq under the ticker ARXS, with Goldman Sachs, Morgan Stanley, and Jefferies acting as joint bookrunners. The IPO’s size and valuation signal robust investor confidence in defense‑related supply chains, potentially setting a benchmark for future listings in the sector and highlighting the sector’s resilience amid geopolitical shifts for companies seeking capital.